BeiGene, Ltd.

HKSE 6160.HK

BeiGene, Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -30.23%

BeiGene, Ltd. Return on Capital Employed (ROCE) is -30.23% for the year ending December 31, 2023, a 9.44% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

BeiGene, Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -33.38%, a -63.49% change year over year.
BeiGene, Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -20.42%, a 44.26% change year over year.
BeiGene, Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -36.63%, a 48.46% change year over year.
BeiGene, Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -71.07%, a -104.48% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

HKSE: 6160.HK

BeiGene, Ltd.

CEO	Mr. John V. Oyler
IPO Date	Aug. 8, 2018
Location	Hong Kong
Headquarters	55 Cambridge Parkway
Employees	10,600
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years